Oncogenic AKTivation of translation as a therapeutic target

被引:0
|
作者
A C Hsieh
M L Truitt
D Ruggero
机构
[1] School of Medicine,Department of Urology
[2] Helen Diller Family Comprehensive Cancer Center,Division of Hematology/Oncology
[3] University of California,undefined
[4] San Francisco,undefined
[5] University of California,undefined
[6] San Francisco,undefined
来源
British Journal of Cancer | 2011年 / 105卷
关键词
AKT; eIF4E; translational control; ribosome; PI3K; mTOR;
D O I
暂无
中图分类号
学科分类号
摘要
The AKT signalling pathway is a major regulator of protein synthesis that impinges on multiple cellular processes frequently altered in cancer, such as proliferation, cell growth, survival, and angiogenesis. AKT controls protein synthesis by regulating the multistep process of mRNA translation at every stage from ribosome biogenesis to translation initiation and elongation. Recent studies have highlighted the ability of oncogenic AKT to drive cellular transformation by altering gene expression at the translational level. Oncogenic AKT signalling leads to both global changes in protein synthesis as well as specific changes in the translation of select mRNAs. New and developing technologies are significantly advancing our ability to identify and functionally group these translationally controlled mRNAs into gene networks based on their modes of regulation. How oncogenic AKT activates ribosome biogenesis, translation initiation, and translational elongation to regulate these translational networks is an ongoing area of research. Currently, the majority of therapeutics targeting translational control are focused on blocking translation initiation through inhibition of eIF4E hyperactivity. However, it will be important to determine whether combined inhibition of ribosome biogenesis, translation initiation, and translation elongation can demonstrate improved therapeutic efficacy in tumours driven by oncogenic AKT.
引用
收藏
页码:329 / 336
页数:7
相关论文
共 50 条
  • [21] The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target
    Blevins, Melanie A.
    Huang, Mingxia
    Zhao, Rui
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (06) : 981 - 990
  • [22] Exploring SLC16A1 as an Oncogenic Regulator and Therapeutic Target in Cholangiocarcinoma
    Huang, Jianxin
    Liu, Fahui
    Liu, Donghua
    Tang, Shihang
    Shen, Dongyan
    JOURNAL OF CANCER, 2024, 15 (12): : 3794 - 3808
  • [23] Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers
    Vizkeleti, Laura
    Spisak, Sandor
    CELLS, 2023, 12 (13)
  • [24] PCAT1: An oncogenic lncRNA in diverse cancers and a putative therapeutic target
    Ghafouri-Fard, Soudeh
    Dashti, Sepideh
    Taheri, Mohammad
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2020, 114
  • [25] GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma
    Gotovac, Jovana R.
    Liu, David S. H.
    Yates, Michael J.
    Milne, Julia, V
    Macpherson, Arthi A.
    Simpson, Kaylene J.
    Eslick, Guy D.
    Mitchell, Catherine
    Duong, Cuong P.
    Phillips, Wayne A.
    Clemons, Nicholas J.
    JOURNAL OF PATHOLOGY, 2020, 252 (03): : 317 - 329
  • [26] Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma
    Slater, K.
    Hoo, P. S.
    Buckley, A. M.
    Piulats, J. M.
    Villanueva, A.
    Portela, A.
    Kennedy, B. N.
    CANCER AND METASTASIS REVIEWS, 2018, 37 (2-3) : 335 - 345
  • [27] The adenosine A2A receptor is a therapeutic target in neurological, heart and oncogenic diseases
    Franco, Rafael
    Lillo, Alejandro
    Navarro, Gemma
    Reyes-Resina, Irene
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2022, 26 (09) : 791 - 800
  • [28] COL1A1: A novel oncogenic gene and therapeutic target in malignancies
    Li, Xue
    Sun, Xiaodong
    Kan, Chengxia
    Chen, Bing
    Qu, Na
    Hou, Ningning
    Liu, Yongping
    Han, Fang
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 236
  • [29] DCLK1 and its oncogenic functions: A promising therapeutic target for cancers
    Ye, Liu
    Liu, Beibei
    Huang, Jingling
    Zhao, Xiaolin
    Wang, Yuan
    Xu, Yungen
    Wang, Shuping
    LIFE SCIENCES, 2024, 336
  • [30] Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma
    K. Slater
    P. S. Hoo
    A. M. Buckley
    J. M. Piulats
    A. Villanueva
    A. Portela
    B. N. Kennedy
    Cancer and Metastasis Reviews, 2018, 37 : 335 - 345